Search results | bristol-myers squibb

Bristol-Myers Squibb eyes big deal, biotech rumour mill

…pharma company, decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb .  The Wall Street Journal reports that Bristol-Myers has been kicking tires around the industry, most recently at Biogen Idec . The Journal‘s sources say BMS looked closely at a Biogen buyout in recent months. Before that, it hired financial advisers to analyze a possible deal for Shire . Biogen has a $39 bi…

Partnering with Bristol-Myers Squibb: String of Pearls approach to partnering

Bristol-Myers Squibb (BMS) is a top pharmaceutical company discovery, development and commercialization of medicinal products worldwide. The company has one core focus to use a combination of its big pharma expertise with biotech entrepreneurialism and agility. The company’s products focus on cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders. Bristol-Myers Squibb has an active partner…

Bristol-Myers Squibb: M&A activity 2005-2013

Bristol-Myers Squibb (BMS) has announced 9 M&A deals since 2005, with the lead deals being the acquisitions of Amylin, Inhibitex and Medarex. Abstracted from: Partnering Deals and Alliances with Bristol-Myers Squibb Bristol-Myers Squibb has a steady record of growth through acquisition, with an average of one to two major acquisition every year, although 2012 was particularly busy with three major acquisitions. The following figure shows the…

Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a top pharmaceutical company based in New York, NY, USA. The company was founded in 1858. Bristol-Myers Squibb is engaged in the discovery, development and commercialization of medicinal products worldwide. The company has one core focus to use a combination of its big pharma expertise with biotech entrepreneurialism and agility. The company’s products focus on cancer, cardiovascular disease, diabetes, hepatitis B,…

Dealmakers weekly review – July 3 2012 – Amylin, Bristol-Myers Squibb, AstraZeneca, Biogen Idec, Celgene, Inhibrx

…he weeks dealmaking The review The major deal story from last week was the $5.3 billion acquisition of Amylin by Bristol-Myers Squibb. The subsequent $3.4 billion collaboration and marketing pact between Bristol-Myers Squibb and AstraZeneca for Amylin’s diabetes portfolio, was key to the BMS-Amylin transaction. On the M&A front in addition to the above, the other major deal of the week was the $1.2 billion acquisition of Robust Sun Hold…

Partnering Agreements with Bristol-Myers Squibb 2005-2012

This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identif…

Bristol-Myers Squibb Foundation announces grants focussed on prevention, diagnosis and care of Hepatitis B and Hepatitis C in Asia

The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope: Awareness, Prevention and Care umbrella program which is committed to reducing hepatitis-related health disparities in Asia.  The grant recipients, which range in scope from national and regional government health, charitable non-profit and advocac…

Bristol-Myers Squibb and Meso Scale Discovery enter agreement to develop diagnostic assays for Alzheimer’s disease

Bristol-Myers Squibb Company and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer’s disease research. Under the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer’s disease research and drug d…

Amylin shares rocket up on report of $3.5 billion buyout offer by Bristol-Myers Squibb

…in a telephone interview. “There are much bigger commercial organizations and companies that probably more than Bristol need to augment their franchises.” Amylin jumped 54 percent to $23.77 at the close in New York for the biggest single-day increase since August 1999. The shares have more than doubled in the last 12 months. Bristol- Myers, based in New York, was unchanged at $33.67, and has gained 25 percent in the last 12 months. Jennifer Maue…

Bristol-Myers Squibb grabs pharma partners deal to Biocon’s oral insulin amid diabetes growth

In a pharma partners agreement, Biocon & Bristol-Myers Squibb, both top biotech/pharma companies, have agreed to sign on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin. Under the terms of the pharma partners agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials…

bannerpng
cbpf14banner300x150jpg
current-partnering-300x150jpg
RSS Feed Linked In Twitter

Latest Tweets

ca300x150gif
nlsd2014jpg
biotech-china-300-x150newjpg